BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND KDM6A, O15550, UTX, 7403, ENSG00000147050, DKFZp686A03225, RP13-886N14_3, MGC141941, bA386N14_2 AND Prognosis
12774 results:

  • 1. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian cancer.
    Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
    Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
    Zhang Q; Zhong ZZ; Wu T; He YQ
    BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer.
    Tanemura M; Furukawa K; Mikamori M; Asaoka T; Yasuoka H; Marukawa D; Urata Y; Yamada D; Kobayashi S; Eguchi H
    Sci Rep; 2024 May; 14(1):10199. PubMed ID: 38702437
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer.
    Ren J; Wu S; Su T; Ding J; Chen F; Li J; Wang Z; Han L; Wu Z
    Cancer Med; 2024 May; 13(9):e7229. PubMed ID: 38698688
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pituitary abscess: a descriptive analysis of a series of 19 patients-a multi-center experience.
    Xue Q; Shi X; Fu X; Yin Y; Zhou H; Liu S; Sun Q; Meng J; Bian L; Tan H; He H
    Eur J Med Res; 2024 May; 29(1):262. PubMed ID: 38698484
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian cancer.
    Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
    In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Targeting KRAS in pancreatic cancer.
    Stickler S; Rath B; Hamilton G
    Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
    Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
    World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Lateral lymph node metastasis in papillary thyroid cancer: Is there a difference between PTC and PTMC?
    Ma W; Guo Y; Hua T; Li L; Lv T; Wang J
    Medicine (Baltimore); 2024 Apr; 103(17):e37734. PubMed ID: 38669400
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cardiovascular mortality risk in patients with ovarian cancer: a population-based study.
    Hu ZL; Yuan YX; Xia MY; Li Y; Yang Y; Wang SN; Meng XZ; Sun MY; Wang N
    J Ovarian Res; 2024 Apr; 17(1):88. PubMed ID: 38664732
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
    Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
    J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
    Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
    BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. CircPHGDH downregulation decreases papillary thyroid cancer progression through miR-122-5p/PKM2 axis.
    Shen J; Ma Z; Yang J; Qu T; Xia Y; Xu Y; Zhou M; Liu W
    BMC Cancer; 2024 Apr; 24(1):511. PubMed ID: 38654205
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic value of combined psoas muscle mass and controlling nutritional status in patients with pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Kuwabara S; Takeuchi Y; Sato O; Mizota T; Ichinokawa M; Murakawa K; Aoki Y; Ishido K; Ono K; Hirano S
    BMC Surg; 2024 Apr; 24(1):116. PubMed ID: 38643112
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genetic diagnosis of endocrine disorders in Cyprus through the Cyprus Institute of Neurology and Genetics: an ENDO-ERN Reference Center.
    Neocleous V; Fanis P; Toumba M; Skordis N; Phylactou LA
    Orphanet J Rare Dis; 2024 Apr; 19(1):167. PubMed ID: 38637882
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Double pituitary adenomas: report of two cases and systematic review of the literature.
    Zhang Y; Gong X; Pu J; Liu J; Ye Z; Zhu H; Lu L; Pan H; Deng K; Yao Y
    Front Endocrinol (Lausanne); 2024; 15():1373869. PubMed ID: 38628582
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.
    Shen L; Li A; Cui J; Liu H; Zhang S
    J Ovarian Res; 2024 Apr; 17(1):82. PubMed ID: 38627854
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [Gonadoblastoma: Clinicopathological study and literature review of 3 cases].
    Bao ML; Li X; Chen G; Li H; Chen W; Li HX
    Zhonghua Nan Ke Xue; 2023 Jul; 29(7):634-638. PubMed ID: 38619412
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A 15-Inflammation-Related Gene Signature Predicts the prognosis of Patients With Pancreatic Ductal Adenocarcinoma.
    Sun X; Song H; Sun X; Liao C; Wang G; Xu Y; Li L; Han Y; Xu C; Wang W; Cai S; Liang H; Yu H
    Cancer Invest; 2024 Mar; 42(3):226-242. PubMed ID: 38616304
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 639.